Design and synthesis of potent, orally bioavailable dihydroquinazolinone inhibitors of p38 MAP kinase

The development of potent, orally bioavailable (in rat) and selective dihydroquinazolinone inhibitors of p38α MAP kinase is described. These analogues are hybrids of a pyridinylimidazole p38α inhibitor reported by Merck Research Laboratories and VX-745. Optimization of the C-5 phenyl and the C-7 pip...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Bioorganic & medicinal chemistry letters 2003-01, Vol.13 (2), p.277-280
Hauptverfasser:	Stelmach, John E., Liu, Luping, Patel, Sangita B., Pivnichny, James V., Scapin, Giovanna, Singh, Suresh, Hop, Cornelis E.C.A., Wang, Zhen, Strauss, John R., Cameron, Patricia M., Nichols, Elizabeth A., O'Keefe, Stephen J., O'Neill, Edward A., Schmatz, Dennis M., Schwartz, Cheryl D., Thompson, Chris M., Zaller, Dennis M., Doherty, James B.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Area Under Curve Biological and medical sciences Biological Availability Drug Design Enzyme Inhibitors - chemical synthesis Enzyme Inhibitors - pharmacokinetics Enzyme Inhibitors - pharmacology In Vitro Techniques Medical sciences Microsomes, Liver - drug effects Microsomes, Liver - metabolism Miscellaneous Mitogen-Activated Protein Kinases - antagonists & inhibitors Models, Molecular Molecular Conformation Monocytes - drug effects Monocytes - metabolism p38 Mitogen-Activated Protein Kinases Pharmacology. Drug treatments Quinazolines - chemical synthesis Quinazolines - pharmacology Rats Structure-Activity Relationship Tumor Necrosis Factor-alpha - antagonists & inhibitors Tumor Necrosis Factor-alpha - biosynthesis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!